Expedition Therapeutics key facts
as of Oct 2026- Operator of biopharmaceutical development services intended for translational research and global licensing purposes.
- Expedition Therapeutics is valued at approximately $1.0B as of Oct 2026, set at its Series B, Aug 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $165.0M across 1 recorded rounds; the latest was Series B ($115.0M) in Aug 2026.
- Notable investors include General Atlantic, RA Capital Management, Novo Holdings, Venrock, Forbion — 14 tracked in total.
- Status: Privately Held (backing).
Valued at $1.0B at its Series B, Aug 2026. Nothing has traded since.
- ·The post-money valuation on its round
- ·The complete investor list: 14 names
- ·Watch Expedition Therapeutics: the Monday email on marks, rounds and moves
Expedition Therapeutics funding rounds
1 roundsWho backs Expedition Therapeutics
14+Expedition Therapeutics valuation
Expedition Therapeutics was valued at $1 billion at its Series B in Aug 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, Expedition Therapeutics's record added 1 funding round.
How much has Expedition Therapeutics raised?
Expedition Therapeutics has raised $165 million in total; 1 of its rounds is on record. The largest on record was an $115 million Series B in Aug 2026. 1 of the rounds disclosed a post-money valuation.
Expedition Therapeutics investors
14 investors are on record for Expedition Therapeutics, including General Atlantic, RA Capital Management, Novo Holdings and Venrock. By type, the record holds 4 hedge funds, 3 venture capital firms and 1 asset manager. 1 of them led a round. The Series B in Aug 2026 drew 13 investors.
About Expedition Therapeutics
Operator of biopharmaceutical development services intended for translational research and global licensing purposes. The company's platform identifies and in-licenses novel therapeutic candidates, conducts preclinical and clinical validation, manages regulatory pathways and commercialization partnerships, enabling pharmaceutical firms and investors to access promising assets from emerging markets, accelerate development timelines, and expand international pipelines efficiently.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 3
- Website
- expeditiontx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.